Ignite Creation Date:
2024-05-06 @ 9:46 AM
Last Modification Date:
2024-10-26 @ 12:19 PM
Study NCT ID:
NCT03076372
Status:
UNKNOWN
Last Update Posted:
2018-02-27
First Post:
2017-03-01
Brief Title:
A Study Evaluating MM-310 in Patients With Solid Tumors
Sponsor:
Merrimack Pharmaceuticals
Organization:
Merrimack Pharmaceuticals
Study Overview
Official Title:
A Phase-1 Study Evaluating the Safety Pharmacology and Preliminary Activity of MM-310 in Patients With Solid Tumors
Status:
UNKNOWN
Status Verified Date:
2018-02
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
MM-310 is a liposomal formulation of a docetaxel prodrug that targets the EphA2 receptor on cancer cells Docetaxel is an approved chemotherapeutic drugThis study is a Phase 1 open-label study of MM-310 in patients with solid tumors In the first part of the study MM-310 will be assessed as a monotherapy until a maximum tolerated dose MTD is established After an MTD of MM-310 as a monotherapy is established an expansion cohort and MM-310 in combination with other therapies will be assessed
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None